The PAPILLON trial subgroup analysis highlights a significant breakthrough for patients with EGFR exon 20 NSCLC. This study evaluated amivantamab combined with chemotherapy as a first-line therapy. Specifically, researchers focused on the Chinese mainland population to validate findings from the global phase 3 study. Consequently, the results suggest that this combination significantly improves clinical outcomes compared to standard chemotherapy alone. Moreover, the data provides robust evidence for regional clinical application.

Trial Design and Methodology

The PAPILLON study was a randomized, open-label, multicenter trial. It enrolled 87 treatment-naïve patients in China with locally advanced or metastatic non-small-cell lung cancer. These patients all possessed EGFR exon 20 insertion mutations. Furthermore, the study randomly assigned participants to receive either amivantamab plus carboplatin-pemetrexed or chemotherapy alone. The primary endpoint was progression-free survival (PFS) as determined by a blinded independent central review. In addition, secondary endpoints included objective response rate and overall survival.

Significant Efficacy Results

Patients receiving the combination therapy showed a markedly longer median PFS of 12.3 months. In contrast, those in the chemotherapy group had a median PFS of 6.7 months. Therefore, the combination reduced the risk of disease progression or death by approximately 53%. Furthermore, the objective response rate (ORR) was substantially higher in the amivantamab group at 71.8%, compared to 48.9% for the chemotherapy group. Thus, these figures demonstrate a significant clinical benefit for those with EGFR exon 20 NSCLC.

Safety Profile of EGFR exon 20 NSCLC Treatment

The safety results remained consistent with the broader PAPILLON trial population. Common adverse events included neutropenia, anemia, and rash. Importantly, no new safety signals emerged during this subgroup analysis. However, clinicians must still monitor for potential infusion-related reactions. No patients discontinued the amivantamab treatment due to related adverse events. Consequently, this suggests a manageable safety profile for most individuals.

Conclusion for Clinical Practice

This subgroup analysis confirms that the combination of amivantamab and chemotherapy is effective for Chinese patients. The data supports its use as a standard first-line treatment option. Consequently, clinicians may consider this regimen to improve survival outcomes in this specific patient population. Additionally, these findings align with international results, reinforcing the global utility of this treatment strategy.

Frequently Asked Questions

What is the benefit of adding amivantamab to chemotherapy in EGFR exon 20 NSCLC?

Adding amivantamab significantly extends progression-free survival and increases the objective response rate compared to chemotherapy alone in patients with EGFR exon 20 insertion mutations.

Is the safety profile of this combination manageable for patients?

Yes, the safety profile was consistent with previous reports. Common side effects include rash and hematological issues, but no new safety concerns were identified in the Chinese subgroup.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. The information provided should not be used for diagnosing or treating a health problem or disease. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

Tang K et al. Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial. Chin Med J (Engl). 2026 May 26. doi: 10.1097/CM9.0000000000004134. PMID: 42192224.

Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023;389(22):2039-2051. doi: 10.1056/NEJMoa2306441.